Dermatologic manifestations of Sjögren syndrome

Journal of Cutaneous Medicine and Surgery

Volumn 15, Issue 1, 2011, Pages 8-14

  Kittridge, Ashley ^a   Routhouska, Shannon B ^a   Korman, Neil J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; ARTIFICIAL TEAR; AZATHIOPRINE; CEVIMELINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKERATIN; DAPSONE; ERYTHROMYCIN; FLUORIDE; HYDROXYCHLOROQUINE; INVOLUCRIN; LEFLUNOMIDE; LOTEPREDNOL; LUBRICATING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PILOCARPINE; RIMEXOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG;

ANNULAR ERYTHEMA; ARTICLE; BLEPHARITIS; CLINICAL FEATURE; CORNEA ULCER; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; CUTANEOUS VASCULITIS; DERMATITIS; DISEASE COURSE; DRUG MEGADOSE; DRY EYE; EYE DISCOMFORT; EYELID; HUMAN; HYPERPIGMENTATION; MORTALITY; MOUTH HYGIENE; NONHODGKIN LYMPHOMA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAYNAUD PHENOMENON; RISK ASSESSMENT; SJOEGREN SYNDROME; SKIN BURNING SENSATION; SKIN DEFECT; SKIN MANIFESTATION; SKIN PRURITUS; SWEATING; SYMPTOMATOLOGY; THRUSH; VAGINAL DRYNESS; VASCULITIS; XERODERMA; XEROPHTHALMIA; XEROSIS; XEROSTOMIA;

HUMANS; ICHTHYOSIS; RAYNAUD DISEASE; SJOGREN'S SYNDROME; SKIN DISEASES; VASCULITIS; XEROSTOMIA;

EID: 79951783467     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2010.09033     Document Type: Article

References (38)

1. Derk C, Vivino F. A primary care approach to Sjögren's syndrome. Postgrad Med 2004;116:49-65.
2. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
3. Connolly MK. Sjögren's syndrome. Semin Cutan Med Surg 2001;20:46-53.
4. Fox RI, Stern M, Michelson P. Update in Sjögren's syndrome. Curr Opin Rheumatol 2000;12:391-8.
5. Fox RI, Tornnwall J, Michelson P. Current issues in the diagnosis and treatment of Sjögren's syndrome. Curr Opin Rheumatol 1999;11:364-71.
6. Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjögren's syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001;76:593-9. (Pubitemid 32525134)
7. Fox R. Sjögren's syndrome. Lancet 2005;366:321-31.
8. Fox R. Liu A. Sjögren's syndrome in dermatology. Clin Dermatol 2006;24:393-413.
9. Rencic A, Nousari H. Other rheumatologic diseases. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. 1st ed. New York: Mosby; 2003. p. 636-8.
10. Bernacchi E, Amato L, Parodi A, et al. Sjögren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 2004;22:55-62. (Pubitemid 38232810)
11. Provost TT, Watson R. Cutaneous manifestations of Sjögren's syndrome. Rheum Dis Clin North Am 1992;18:609-16.
12. Bernacchi E, Bianchi B, Amato L, et al. Xerosis in primary Sjögren syndrome: immunohistochemical and functional investigations. J Dermatol Sci 2005;39:53-5. (Pubitemid 40835833)
13. Katayama I, Yokozeki H, Nishioka K. Impaired sweating as an exocrine manifestation in Sjögren-syndrome. Br J Dermatol 1995;133:716-20.
14. Katayama I, Kayano T, Nishioka K. Prevalence of eyelid dermatitis in primary Sjögren's syndrome. Int J Dermatol 1994;33:421-4. (Pubitemid 24223161)
15. Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sjögren's syndrome. Clin Exp Rheumatol 2008;26 Suppl 51:S66-71.
16. Ramos-Casals M, Anaya J, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome. Medicine 2004;83:96-106.
17. Alexander EL, Provost TT. Cutaneous manifestations of primary Sjögren's syndrome: a reflection of vasculitis and association with anti-Ro(SSA) antibodies. J Invest Dermatol 1983;80:386-91. (Pubitemid 13134117)
18. Ioannidis JPA, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7. (Pubitemid 34214255)
19. Skopouli FN, Dafni U, Ioannidis JPA, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304. (Pubitemid 30235981)
20. Kyle R, Gleich G, Bayrid E, Vaughn JH. Benign hypergammaglobulinemic purpura of Waldenstrom. Medicine 1971;50:113-23.
21. Gemignani R, Marbini A, Pavesi G, et al. Peripheral neopathy associated with primary Sjögren's syndrome. J Neurol Neurosurg Psychiatry 1994;57:983-6. (Pubitemid 24251068)
22. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996;39:767-72.
23. Ramos-Casals M, Brito-Zeron P, Yague J, et al. Hypocomplementemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology 2005;44:89-94. (Pubitemid 40124338)
24. Haimowitz JE, McCauliffe DP, Seykora J, Werth VP. Annular erythema of Sjögren's syndrome in a white woman. J Am Acad Dermatol 2000;42:1069-73. (Pubitemid 30368679)
25. Katayama I, Teramoto N, Arai H, et al. Annular erythema. A comparative study of Sjögren's syndrome with subacute cutaneous lupus erythematosus. Int J Dermatol 1991;30:635-9.
26. Meijer JM, Schonland SO, Palladini G, et al. Sjögren's syndrome and localized nodular cutaneous amyloidosis. Coincidence or a distinct clinical entity? Arthritis Rheum 2008;58:1992-9.
27. Yamomoto T, Ohi M, Nishioka K. Lymphomatoid papulosis associated with Sjögren's syndrome. J Dermatol 2002;29:174-7. (Pubitemid 34289031)
28. Tsuboi H, Katsuoka K. Ulcerative lichen planus associated with Sjögren's syndrome. J Dermatol 2007;34:131-4. (Pubitemid 46103054)
29. Tait CP, Yu LL, Rohr J. Sjögren's syndrome and granulomatous panniculitis. Aust J Dermatol 2000;41:187-9.
30. Tsuruta D, Matsumura-Oura A, Ishii M. Subcorneal pustular dermatosis and Sjögren's syndrome. Int J Dermatol 2005;44:955-7. (Pubitemid 41723762)
31. Shimizu S, Nakamura Y, Togawa Y, et al. Erythema elevatum diutinum with primary Sjögren's syndrome associated with IgA antineutrophil cytoplasmic antibody. Br J Dermatol 2008;159:733-72.
32. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
33. Fox RI, Robinson CA, Curd JG, et al. Sjögren's syndrome proposed criteria for classification. Arthritis and Rheumatism 1986;29:577-85. (Pubitemid 16056825)
34. Thanou-Stavraki A, James JA. Primary Sjögren's syndrome: current and prospective therapies. Semin Arthritis Rheum 2008;37:273-92. (Pubitemid 351389478)
35. Vivino F, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159:174-81. (Pubitemid 29055106)
36. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54. (Pubitemid 40283042)
37. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987;16:772-8. (Pubitemid 17055878)
38. Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol 1985;13:193-200. (Pubitemid 15007110)